新規抗癌剤カペシタビンの研究開発
スポンサーリンク
概要
- 論文の詳細を見る
Capecitabine (N^4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine) is a novel oral fluoropyrimidine carbamate, which was designed to be sequentially converted to 5-fluorouracil (5-FU) by three enzymes located in the liver and in tumors. N^4-alkoxycarbonyl-5'-deoxy-5-fluorocytidine derivatives including capecitabine pass intact through the intestinal tract and are sequentially converted to 5-FU by a cascade of the three anzymes. The first step is the conversion to 5'-deoxy-5-fluorocytidine (5'-DFCR) by carboxylesterase located in the liver, then to 5'-deoxy-5-fluorouridine (5'-DFUR) by cytidine deaminase highly expressed in the liver and various solid tumors, and finally to 5-FU by thymidine phosphorylase (dThdPase) preferentially located in tumor tissues. Among large numbers of the derivatives, capecitabine was selected based on its susceptibility to hepatic carboxylesterase, oral bioavailability in monkeys and efficacy in a human cancer xenograft. Capecitabine given orally yielded substantially higher concentrations of 5-FU within tumors than in plasma or normal tissue (muscle). The tumor 5-FU levels were also much higher than those achieved by intraperitoneal administration of 5-FU at equi-toxic doses. This tumor selective delivery of 5-FU ensured greater efficacy and a more favourable safety profile than with other fluoropyrimidines. In 24 human cancer xenograft models studied, capecitabine was more effective at a wider dose range and had a broader spectrum of antitumor activity than 5-FU, UFT or its intermediate metabolite 5'-DFUR. The susceptibility of the xenografts to capecitabine correlated with tumor dThdPase levels. Moreover, the conversion of 5'-DFUR to 5-FU by dThdPase in tumor was insufficient in a xenograft model refractory to capecitabine. In addition, the efficacy of capecitabine was enhanced by dThdPase up-regulators, such as by taxanes and cyclophosphamide and by X-ray irradiation. The efficacy of capecitabine may, therefore, be optimized by selecting the most appropriate patient population based on dThdPase status and/or by combining it with dThdPase up-regulators. Capecitabine has additional characteristics not found with 5-FU, such as potent antimetastatic and anticachectic actions in mouse tumor models. With these profiles, capecitabine may have substantial potential in cancer treatment.
- 社団法人日本薬学会の論文
- 1999-12-01
著者
関連論文
- 67 新規コレシストキニンタイプB受容体阻害物質Ro 09-1468の構造(ポスター発表の部)
- In Vitro 抗原性試験法の開発
- p27ノックアウトマウスにおける成長の促進と多臓器腫大
- 細胞周期調節のT細胞分化に与える影響 : p27ノックアウトマウスを用いた解析
- 経口抗癌剤カペシタビンの体内動態:トリブルプロドラッグ投与後の5-FUの腫瘍選択的分布を定量的に理解する手段としての生理学的薬物速度論モデル
- トリプルプロドラッグ、capecitabine の生理学的モデルによる薬物動態・薬効の予測 : マウスヒト腫瘍 xenograft model からのヒト抗癌活性の予測
- 新規カテコール-0-メチルトランスフェラーゼ阻害薬 Tolcapone のヒトにおける PK-PD 解析
- 新規抗癌剤カペシタビンの研究開発
- 25 新規ホスホリパーゼC阻害物質Ro 09-1450の構造(ポスター発表の部)
- 40 新規フォスフォリパーゼC阻害物質Hispidospermidinの構造決定(口頭発表の部)
- 24 10-ヒドロキシ-ジヒドロシンコニジン誘導体の立体選択的合成
- Prolonged Effect of 5-Fluorouracil and Its Derivatives on Apoptosis Induction and Mitotic Inhibition in the Intestinal Epithelium of Male BDF1 Mice
- Flow Cytometric Analysis for the Evaluation of the Rat Sperm Viability and Number in the Male Reproductive Toxicity Studies
- 161. 病的条件下における結合組織由来の biologically active cleavage products (Chemical mediators)
- 医薬品の創薬・開発研究における新しい薬物安全性評価 (特集 オーダーメイド医療--臨床応用への着実なアプローチ)
- 実験データの監査(監査と診断)
- ラットに対する腎機能検査の実際とその問題点 : PSP排泄試験, クレアチニン クリアランス試験
- 28. アレルギー性炎症の病態機序 : 増殖性肉芽性炎症巣における脂質組成の変動とその意義(chemical mediators)
- 142.アレルギー性炎症における微少循環系の傷害機序(その1)(chemical mediatorsおよび類似物質)
- 医薬品開発過程におけるトキシコキネティックスの有用性と問題点